Competitive inhibitors of galactocerebrosidase (GALC) could be candidates for
pharmacological chaperone therapy of patients with Krabbe disease. The known and
selective nortropane-type iminosugar galacto-noeurostegine has been found
to competitively inhibit GALC with Ki = 7 μM at pH 4.6, which
is 330-fold more potent than the analogous deoxynoeurostegine. It was shown
through X-ray protein crystallography that galacto-noeurostegine binds to
the active site of GALC in its bicyclic form.